Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Feasibility and Significance of Preclinical Diagnosis in Hypertrophic Cardiomyopathy

Efthimiadis, Georgios K. MD, PhD*; Pagourelias, Efstathios D. MD, PhD*†; Hadjimiltiades, Stavros MD, PhD*; Meditskou, Soultana MD, PhD; Karvounis, Haralampos MD, PhD*; McKenna, William J. MD, PhD§

doi: 10.1097/CRD.0000000000000076
Review Articles
Buy

Preclinical diagnosis in hypertrophic cardiomyopathy (HCM) refers to the detection of functional or histopathological abnormalities in subjects who carry any HCM-causing gene mutation, before or even without the development of left ventricular hypertrophy [genotype(+)/phenotype(-)subjects]. The concept that HCM pathology may exist in the absence of left ventricular hypertrophy is quite old but the ability to recognize the presence of early myocardial changes is quite new. Lessons from animal models have shown that in experimental human HCM, myocardial cell mechanical dysfunction precedes histopathological changes, such as myocyte disarray, fibrosis, and hypertrophy. Several clinical reports have demonstrated that the majority of HCM genotype(+)/phenotype(-) subjects display myocardial functional or histopathological changes, such as reduced tissue Doppler imaging-derived systolic and diastolic velocities, abnormal electrocardiogram, cardiac magnetic resonance-visualized myocardial crypts, mitral leaflet elongation, and evidence of a fibrotic state, such as increased type I procollagen synthesis, cardiac magnetic resonance-increased myocardial extracellular volume, and late gadolinium myocardial enhancement. All these signs have been proposed as preclinical markers of HCM. At present the separation of such a group of subjects in the early phase of their disease provides the opportunity to test new therapies to prevent the development of fibrosis, hypertrophy, and dysfunction.

From the *Cardiomyopathies Laboratory, First Department of Cardiology, AHEPA Hospital, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece; Third Cardiology Department, Hippokrateion Hospital, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece; Laboratory of Histology and Embryology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece; and §Institute of Cardiovascular Science, University College London, London, England.

Disclosure: The authors have no conflicts of interest to report.

Correspondence: Efstathios D. Pagourelias, MD, PhD, Third Cardiology Department, Hippokrateion University Hospital, Medical School, Aristotle University of Thessaloniki, Konstantinoupoleos 49 Str. PC: 54642, Thessaloniki, Greece. E mail: statpag@yahoo.gr.

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.